接受 upfront 保乳手术的乳腺癌患者的大分割放疗联合瘤床同步推量(Hi-RISE):一项 III 期随机对照试验的研究方案
这是一项前瞻性、多中心、随机对照、非劣效性 III 期试验,计划招募 2904 例接受 upfront 保乳手术的乳腺癌患者,按 1:1 随机分为大分割放疗联合瘤床同步推量(HFRTsib)组与常规分割放疗序贯推量(CFRTseq)组,主要终点为 5 年局部区域控制率。HFRTsib 组全乳照射 40 Gy/15 次,瘤床同步推量 48 Gy/15 次;CFRTseq 组全乳照射 50 Gy/25 次,瘤床序贯推量 10 Gy/5 次。
要点
- HFRTsib 组处方剂量为全乳 40 Gy/15 次,瘤床同步推量 48 Gy/15 次。
- CFRTseq 组处方剂量为全乳 50 Gy/25 次,瘤床序贯推量 10 Gy/5 次。
- 主要终点为 5 年局部区域控制率,设计为非劣效性检验。
核心结论
- 该试验旨在评估大分割放疗联合瘤床同步推量在保乳术后早期乳腺癌患者中的有效性与安全性。
- 主要终点为局部区域控制率,试验结果预期为保乳术后乳腺癌患者应用大分割放疗提供关键证据。
研究设计与样本
- 前瞻性、多中心、随机对照、非劣效性 III 期试验,计划招募 2904 例接受 upfront 保乳手术的乳腺癌患者。
- 参与者按 1:1 比例随机分为 HFRTsib 组与 CFRTseq 组。
- 所有患者接受全乳照射,腋窝淋巴结阳性者接受额外的区域淋巴结照射,包括内乳照射。
关键数值与推荐
- HFRTsib 组:全乳 40 Gy/15 次,瘤床同步推量 48 Gy/15 次。
- CFRTseq 组:全乳 50 Gy/25 次,瘤床序贯推量 10 Gy/5 次。
- 主要终点为 5 年局部区域控制率,采用非劣效性设计比较 HFRTsib 与 CFRTseq。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effectiveness and safety of moderately hypofractionated radiotherapy (HFRT) in patients undergoing breast-conserving surgery (BCS) has been demonstrated in several pivotal randomized trials. However, the feasibility of applying simultaneous integrated boost (SIB) to the tumor bed and regional node irradiation (RNI) using modern radiotherapy techniques with HFRT needs further evaluation. METHODS: This prospective, multi-center, randomized controlled, non-inferiority phase III trial aims to determine the non-inferiority of HFRT combined with SIB (HFRTsib) compared with conventional fractionated radiotherapy with sequential boost (CFRTseq) in terms of five-year locoregional control rate in breast cancer patients undergoing upfront BCS. A total of 2904 participants will be recruited and randomized in a 1:1 ratio into the HFRTsib and CFRTseq groups. All patients will receive whole breast irradiation, and those with positive axillary nodes will receive additional RNI, including internal mammary irradiation. The prescribed dose for the HFRTsib group will be 40 Gy in 15 fractions, combined with a SIB of 48 Gy in 15 fractions to the tumor bed. The CFRTseq group will receive 50 Gy in 25 fractions, with a sequential boost of 10 Gy in 5 fractions to the tumor bed. DISCUSSION: This trial intends to assess the effectiveness and safety of SIB combined with HFRT in early breast cancer patients following BCS. The primary endpoint is locoregional control, and the results of this trial are expected to offer crucial evidence for utilizing HFRT in breast cancer patients after BCS. TRIAL REGISTRATION: This trial was registered at ClincalTrials.gov (NCT04025164) on July 18, 2019.
引用
- Jin K, Luo J, Yu X, et al. Hypofractionated radiotherapy with simultaneous tumor bed boost (Hi-RISE) in breast cancer patients receiving upfront breast-conserving surgery: study protocol for a phase III randomized controlled trial. Radiat Oncol. 2024. PMID: 38802888. doi:10.1186/s13014-024-02449-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。